Analyst Ratings for Mirum Pharmaceuticals (MIRM)
As of November 20, 2023, a total of 11 analysts have shared their assessments on the stock of Mirum Pharmaceuticals (NASDAQ:MIRM). These analysts’ ratings can be categorized as follows:
– Bullish: 3 analysts
– Somewhat Bullish: 8 analysts
– Indifferent: 0 analysts
– Somewhat Bearish: 0 analysts
– Bearish: 0 analysts
The average price target given by these 11 analysts is $60.82, which suggests a potential upside from the current price of $32.32. It is worth noting that the current average price target has decreased by 17.25% compared to the previous average of $73.50.
To provide a more comprehensive overview, let’s take a look at the analyst ratings from various sources:
The Wall Street Journal:
– Buy: 6 analysts
– Overweight: 1 analyst
– Hold: 0 analysts
– Underweight: 0 analysts
– Sell: 0 analysts
– Consensus: Buy
– High Price Target: $84.00
– Median Price Target: $53.50
– Low Price Target: $34.00
– Average Price Target: $55
TipRanks:
– Strong Buy: 9 analysts
– Buy: 0 analysts
– Hold: 0 analysts
– Sell: 0 analysts
– Average Price Target: $55.44 (93.78% Upside)
Yahoo Finance:
– No. of Analysts: 8
– Avg. Estimate: -0.28
– Low Estimate: -0.5
– High Estimate: -0.13
MarketBeat:
– Consensus Analyst Rating: Buy
– Consensus Analyst Price Target: $51.14 (71.74% Upside)
In summary, the majority of analysts hold a positive outlook on Mirum Pharmaceuticals, with ratings ranging from Buy to Strong Buy. The price targets provided by analysts indicate potential upside for the stock. For more detailed information, please refer to the respective sources.
Mirum Pharmaceuticals, Inc.
MIRM
Neutral
Updated on: 30/11/2023
Weak 
Debt to equity ratio: Buy 
Mirum Pharmaceuticals Stock Analysis: Stable Performance and Positive Growth, but Challenges Remain
On November 20, 2023, Mirum Pharmaceuticals (MIRM) had a relatively stable day in the stock market. The stock opened at $32.44, slightly higher than the previous day’s closing price of $32.35. Throughout the day, the stock traded in a range of $31.94 to $32.52. The trading volume was 25,763, which is significantly lower than the average volume of 523,117 over the past three months.
Mirum Pharmaceuticals has a market capitalization of $1.4 billion. While the company experienced a decline in earnings growth of -44.74% last year, it has seen a positive turnaround this year with earnings growth of +38.65%. Looking ahead, the company is expected to maintain a modest earnings growth of +3.00% over the next five years.
Mirum Pharmaceuticals had an impressive revenue growth rate of +302.66% last year. However, it is important to note that the company’s net profit margin stands at -176.05%, indicating that it is currently operating at a loss.
Mirum Pharmaceuticals’ stock does not have a P/E ratio listed, which suggests that the company may not have positive earnings or is not yet profitable. The Price/Sales ratio is 8.56, indicating that investors are willing to pay a higher price for each dollar of the company’s sales. The Price/Book ratio is 7.89, which suggests that the stock may be trading at a premium compared to its book value.
In comparison to other pharmaceutical companies, Supernus Pharmaceuticals (SUPN) experienced a slight decline of -0.16 (-0.58%) on the same day, while Ironwood Pharmaceuticals (IRWD) had a more significant drop of -0.41 (-4.19%). Ironwood Pharmaceuticals is scheduled to report its next earnings on March 6, 2024, with an EPS forecast of -$0.38. The company reported an annual revenue of $77.1 million last year, with a net loss of -$135.7 million.
Mirum Pharmaceuticals operates in the health technology sector, specifically in the pharmaceuticals: major industry. The company’s corporate headquarters are located in Foster City, California.
In conclusion, on November 20, 2023, Mirum Pharmaceuticals’ stock had a relatively stable performance. While the company has seen positive earnings and revenue growth this year, it is important to consider its current net loss and lack of profitability. Investors should closely monitor the company’s financial performance and future earnings reports to make informed investment decisions.
Mirum Pharmaceuticals Inc: Strong Growth Forecasted for Rare Liver Disease Therapies
On November 20, 2023, Mirum Pharmaceuticals Inc (MIRM) had a median target price of $60.00, according to 9 analysts offering 12-month price forecasts. The high estimate was $78.00, while the low estimate was $38.00.
The consensus among the 9 polled investment analysts was to buy stock in Mirum Pharmaceuticals Inc. This rating has remained unchanged since November.
Looking at the current quarter’s performance, Mirum Pharmaceuticals Inc reported earnings per share of -$0.38 and sales of $50.7 million. These figures were released on March 6.
Mirum Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare liver diseases.
The optimistic price forecasts from the analysts suggest that Mirum Pharmaceuticals Inc is expected to experience significant growth in the coming months. This positive outlook can be attributed to the company’s strong pipeline of potential therapies and its commitment to addressing rare liver diseases.
Investors considering purchasing Mirum Pharmaceuticals Inc stock should take note of the analysts’ recommendations and the positive sentiment surrounding the company. However, it is important to conduct thorough research and analysis before making any investment decisions. Factors such as market conditions, competitor performance, and regulatory approvals should also be taken into consideration.
Overall, the performance of Mirum Pharmaceuticals Inc stock on November 20, 2023, appears promising, with analysts predicting a potential increase of 86.45% from the last recorded price. Investors should closely monitor the company’s progress and any updates that may impact its future performance.
Discussion about this post